Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Allergy and Immunology · Chronic Spontaneous Urticaria

Tracking Your Progress and Looking Ahead

At a Glance

Chronic Spontaneous Urticaria (CSU) progress is tracked using symptom diaries like the UAS7 and UCT to measure daily hives and itch. While CSU can severely impact sleep and mental health, it is usually self-limiting and often goes into remission within one to five years.

Because Chronic Spontaneous Urticaria (CSU) varies from day to day, your doctor cannot rely on a single physical exam to understand your disease [1]. Instead, management depends on two patient-reported tools that help “quantify” how well your treatment is working.

1. The UAS7 (Urticaria Activity Score over 7 days)

This is a daily diary where you record two things for one week: the number of hives (wheals) and the intensity of your itch [2].

How to calculate your daily score (0-6 points):

  • Hives (0-3): 0 (None), 1 (Less than 20), 2 (20-50), 3 (More than 50).
  • Itch (0-3): 0 (None), 1 (Mild - present but not annoying), 2 (Moderate - troublesome but does not interfere with daily activity), 3 (Severe - interferes with daily activity or sleep).

Add these two numbers together each day to get a daily score out of 6. At the end of 7 days, add all the daily scores together for your weekly UAS7 total.

  • The Scale: Scores range from 0 to 42 [3].
  • The Cutoff: A score of 6 or lower is considered “well-controlled” [3][4].
  • The Goal: Ideally, doctors aim for a score of 0, meaning you are completely symptom-free [5].

2. The UCT (Urticaria Control Test)

While the UAS7 looks at one week, the UCT looks at your control over the last four weeks [6]. It consists of four questions about your physical symptoms, quality of life, treatment effectiveness, and overall control [7].

  • The Scale: Scores range from 0 to 16.
  • The Cutoff: A score of 12 or higher indicates your disease is “well-controlled” [8][9].

The Long-Term Outlook (Prognosis)

The most important thing to know about CSU is that for the vast majority of people, it is a self-limiting disease [10]. While it is “chronic,” that does not mean it is permanent.

  • Duration: Many patients find that their CSU naturally resolves within 1 to 5 years [10].
  • Remission: Remission is defined as being symptom-free without the need for medication for at least six months [11].
  • Relapse: If you are on a biologic like omalizumab and stop treatment because your hives have disappeared, be aware that about 50% of patients may experience a relapse, typically within the first year after stopping [12][13]. This is not a failure of the drug; it simply means the underlying immune process hasn’t fully quieted down yet.

The Hidden Burden: Sleep and Mental Health

CSU is more than just “itchy skin.” Research shows that the unpredictable nature of the hives and the constant itch can have a massive impact on your quality of life, causing distress comparable to other major chronic conditions [14][15].

Key areas of concern include:

  • Sleep Disturbance: Constant itching frequently leads to insomnia or poor-quality sleep, which can affect your energy and focus during the day [16][17].
  • Mental Health: Patients with CSU have a significantly higher risk of developing anxiety and depression [18][19].

If you are struggling with these “invisible” symptoms, it is vital to discuss them with your doctor. Holistic management of CSU means treating both the hives on your skin and the toll the condition takes on your mind and body [18].

Back to Home

Common questions in this guide

What is a good UAS7 score for chronic urticaria?
A UAS7 score of 6 or lower means your condition is considered well-controlled. However, the ultimate goal for treatment is a score of zero, meaning you are completely free of hives and itching.
How does the UCT differ from the UAS7?
The Urticaria Control Test (UCT) evaluates your symptom control over the past four weeks using four simple questions. A score of 12 or higher out of 16 indicates that your disease is well-controlled.
How long does chronic spontaneous urticaria last?
For most people, chronic spontaneous urticaria is a self-limiting condition. Many patients find that their hives naturally resolve and go into remission within one to five years, even if it feels permanent right now.
What happens if I stop taking my biologic medication for hives?
If you stop taking a biologic medication like omalizumab after your hives clear up, there is about a 50% chance of experiencing a relapse within the first year. This is not a failure of the drug, but means the underlying immune process is still active.
Can chronic hives cause anxiety or sleep problems?
Yes, the constant itching and unpredictability of chronic hives can severely impact your quality of life. Patients have a significantly higher risk of experiencing sleep disturbances, insomnia, anxiety, and depression.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current UAS7 score, should we consider stepping up or stepping down my treatment?
  2. 2.What is the long-term plan for monitoring my symptoms if I reach a 'zero' score for several months?
  3. 3.If we decide to pause omalizumab, what is our plan for managing a potential relapse in the first few months?
  4. 4.Are my sleep issues and anxiety typical for CSU, and can you recommend resources for the psychological impact of this condition?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations.

    Tawil S, Irani C, Kfoury R, et al.

    International journal of dermatology 2020; (59(8)):893-901 doi:10.1111/ijd.15006.

    PMID: 32638368
  2. 2

    The Urticaria Activity Score-Validity, Reliability, and Responsiveness.

    Hawro T, Ohanyan T, Schoepke N, et al.

    The journal of allergy and clinical immunology. In practice 2018; (6(4)):1185-1190.e1 doi:10.1016/j.jaip.2017.10.001.

    PMID: 29128337
  3. 3

    The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.

    Kolkhir P, Laires PA, Salameh P, et al.

    The journal of allergy and clinical immunology. In practice 2023; (11(2)):610-620.e5 doi:10.1016/j.jaip.2022.11.016.

    PMID: 36481420
  4. 4

    Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.

    Salman A, Ergun T, Gimenez-Arnau AM

    The Journal of dermatological treatment 2020; (31(2)):204-209 doi:10.1080/09546634.2019.1589639.

    PMID: 30821591
  5. 5

    Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria.

    Maurer M, Metz M, Anderson J, et al.

    Allergy 2025; (80(8)):2178-2186 doi:10.1111/all.16598.

    PMID: 40415544
  6. 6

    Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.

    Bérard F, Ferrier Le Bouedec MC, Bouillet L, et al.

    The British journal of dermatology 2019; (180(1)):56-66 doi:10.1111/bjd.16904.

    PMID: 29927483
  7. 7

    Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria.

    Kocatürk E, Kızıltaç U, Can P, et al.

    The World Allergy Organization journal 2019; (12(1)):100009 doi:10.1016/j.waojou.2018.11.007.

    PMID: 30937134
  8. 8

    Adaptation and Validation of the Korean Version of the Urticaria Control Test and Its Correlation With Salivary Cortisone.

    Lee JH, Bae YJ, Lee SH, et al.

    Allergy, asthma & immunology research 2019; (11(1)):55-67 doi:10.4168/aair.2019.11.1.55.

    PMID: 30479077
  9. 9

    Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria.

    Nguyen MTT, Le MH, Vu MN, et al.

    PloS one 2025; (20(8)):e0326445 doi:10.1371/journal.pone.0326445.

    PMID: 40853993
  10. 10

    Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy?

    Metz M, Maurer M

    Allergologie select 2021; (5()):89-95 doi:10.5414/ALX02204E.

    PMID: 33615122
  11. 11

    Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper.

    Sánchez J, Pite H, Gómez RM, et al.

    The Journal of allergy and clinical immunology 2025; (155(3)):1050-1056.e2 doi:10.1016/j.jaci.2024.11.039.

    PMID: 39732405
  12. 12

    Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.

    Ocak M, Soyer O, Buyuktiryaki B, et al.

    Allergologia et immunopathologia 2020; (48(4)):368-373 doi:10.1016/j.aller.2020.03.011.

    PMID: 32467066
  13. 13

    Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.

    Casale TB, Gimenez-Arnau AM, Bernstein JA, et al.

    Dermatology and therapy 2023; (13(11)):2573-2588 doi:10.1007/s13555-023-01040-9.

    PMID: 37776480
  14. 14

    Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.

    Finlay AY, Kaplan AP, Beck LA, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(10)):1715-1721 doi:10.1111/jdv.14384.

    PMID: 28573683
  15. 15

    The Impact of Chronic Urticaria from the Patient's Perspective: A Survey in Five European Countries.

    Balp MM, Vietri J, Tian H, Isherwood G

    The patient 2015; (8(6)):551-8 doi:10.1007/s40271-015-0145-9.

    PMID: 26476961
  16. 16

    The relationship between sleep quality and chronotype differences and urticaria severity in patients with chronic spontaneous urticaria.

    Gurel G, Guler D, Guler HA, et al.

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2024; (33(1)):7-11.

    PMID: 38532655
  17. 17

    An Assessment of Melatonin Levels in the Saliva of Patients with Chronic Urticaria in Comparison with Their Sleep Quality and Dermatologic Quality of Life.

    Bešlić I, Vrtarić A, Škrinjar I, et al.

    Clinics and practice 2026; (16(2)) doi:10.3390/clinpract16020036.

    PMID: 41744519
  18. 18

    Chronic Spontaneous Urticaria: A Review.

    Kolkhir P, Bonnekoh H, Metz M, Maurer M

    JAMA 2024; (332(17)):1464-1477 doi:10.1001/jama.2024.15568.

    PMID: 39325444
  19. 19

    A Meta-Analysis of Observational Studies on the Association of Chronic Urticaria With Symptoms of Depression and Anxiety.

    Huang Y, Xiao Y, Zhang X, et al.

    Frontiers in medicine 2020; (7()):39 doi:10.3389/fmed.2020.00039.

    PMID: 32175322

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider to discuss your UAS7 scores and CSU treatment plan.

Get notified when new evidence is published on chronic idiopathic urticaria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.